✦ LIBER ✦

26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies

✍ Scribed by A. Adjei; R.B. Cohen; W.A. Franklin; J. Molina; S. Hariharan; E. Temmer; S. Brown; L. Maloney; C. Morris; S.G. Eckhardt

Book ID: 118623654
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 82 KB
Volume: 4
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(06)70031-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Detection of BRAF mutations in the tumou

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

✍ Board, R E; Ellison, G; Orr, M C M; Kemsley, K R; McWalter, G; Blockley, L Y; De 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 334 KB

A phase I, open-label, randomized crosso

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

✍ Suzanne Leijen; Patricia M. M. B. Soetekouw; T. R. Jeffry Evans; Marianne Nicols 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 303 KB

Phase I and pharmacokinetic study of cap

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

✍ Maarten J. Deenen, Heinz-Josef Klümpen, Dick J. Richel, Rolf W. Sparidans, Marie 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 299 KB

A phase II open-label randomized study t

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 640 KB

Phase I Expansion and Pharmacodynamic St

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS-RAF Mutations

✍ Zimmer, L.; Barlesi, F.; Martinez-Garcia, M.; Dieras, V.; Schellens, J. H. M.; S 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 613 KB

Erratum to: A phase II open-label random

Erratum to: A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 61 KB